If approved, in what settings will you consider adding aglatimagene besadenovec (CAN-2409) to EBRT as an ADT-sparing strategy in prostate cancer treatment?

CAN-2409 "is an adenoviral replication-defective engineered gene construct, encoding the thymidine kinase gene derived from herpes simplex virus (HSV). Aglatimagene is injected directly into the tumor or target tissue...These tumor cells can then express HSV-thymidine kinase, which converts generic....